Omega (OMGA) - Multiplikator Forward P/S
The future P/S multiple dynamics for Omega Therapeutics (OMGA) are subject to liquidity shortage risks and potential delays in mRNA platform trials. Meanwhile, business development remains independent of macroeconomics and GDP, while the operating model relies on external production outsourcing. The current value of 0.90 represents a metric level that allows an investor to promptly identify overvalued expectations or fundamental sales growth.
Rincian metrik lan analitis perusahaan Omega Therapeutics Corp (OMGA)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Omega Therapeutics|OMGA - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Omega Therapeutics|OMGA - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Omega Therapeutics Corp|OMGA - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Omega Therapeutics|Likuiditas cepet omegatherapeutics.com
- data bathi bisnis lan rasio investasi:
OMGA - Asil keuangan resik|Bathi sing dikarepake Omega Therapeutics|OMGA - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Omega|OMGA - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Omega Therapeutics Corp|OMGA - Bathi operasional sadurunge potongan amortisasi|Bathi resik saben saham (EPS TTM) Omega Therapeutics|OMGA - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan omegatherapeutics.com|OMGA - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Omega Therapeutics
- informasi babagan volume dodolan lan pendapatan:
Analisis umum perusahaan:Omega Therapeutics, Inc. OMGA
Investors use this indicator to determine the degree of overpayment for future cash flows in the absence of current earnings. The expected P/S ratio compares the market value of Omega Therapeutics (OMGA) with revenue forecasts, allowing for an assessment of capitalization potential through the lens of the epigenetic programming platform's development and the prospects for implementing oncology therapy drugs.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Rega forward marang dodolan QGEN|Ionis Pharma - Multiplikator Forward P/S|RGEN - Multiplikator Forward P/S|Avidity Biosciences (RNA) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CRSP (crisprtx.com)|WGS (GeneDx) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|Multiplikator Forward P/S Sarepta Corp (SRPT)|Twist Bioscience - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke Therapeutics Inc STOK|BLFS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Wave Pharma|Rasio rega marang prakiraan pendapatan Maze Therapeutics Inc|sionnatx.com (SION) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Prime Medicine (PRME)|TSHA - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan uniQure Corp QURE|MGTX - Multiplikator forward rega marang pendapatan|REGENXBIO Inc. - Multiplikator Forward P/S|Prakiraan rega marang pendapatan solidbio.com (SLDB)|OCGN: Multiplikator Forward P/S|Pacific Biosciences of California, Inc. (PACB) - Multiplikator Forward P/S|BNTC (Benitec) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan DSGN (Design Corp)|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S LXEO (Lexeo Therapeutics, Inc.)|Multiplikator Forward P/S Korro Bio Inc. KRRO|EDIT - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Silence Therapeutics Corp|proqr.com (PRQR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Codexis|SGMO (Sangamo Therapeutics, Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Nautilus Biotechnology Inc NAUT|Multiplikator Forward P/S MGX|Precision BioSciences Inc. (DTIL) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S GBIO (Generation Bio)|Multiplikator Forward P/S boundlessbio.com BOLD|XCUR: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan IMNN (Imunon, Inc.)|PHIO (phiopharma.com) - Multiplikator forward rega marang pendapatan|MBIO: Rasio rega marang pendapatan sing dikarepake|RNAZ (TransCode Therapeutics Inc.) - Multiplikator Forward P/S|BNGO: Rega forward marang dodolan|Multiplikator Forward P/S APDN|BLUE - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan ImmunoPrecise Antibodies Ltd. IPA|Rega forward marang dodolan OMIC|Regulus Therapeutics - Multiplikator Forward P/S|SYRS - Multiplikator Forward P/S|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON Pharmaceuticals Inc.)|UBX (Unity Bio) - Multiplikator Forward P/S
